| Association of survival and immune-related biomarkers with immunotherapy in patients with non–small cell lung cancer: A meta-analysis and individual patient–level analysis Y Yu, D Zeng, Q Ou, S Liu, A Li, Y Chen, D Lin, Q Gao, H Zhou, W Liao, ... JAMA network open 2 (7), e196879-e196879, 2019 | 210 | 2019 |
| Tumor cell-derived SPON2 promotes M2-polarized tumor-associated macrophage infiltration and cancer progression by activating PYK2 in CRC C Huang, R Ou, X Chen, Y Zhang, J Li, Y Liang, X Zhu, L Liu, M Li, D Lin, ... Journal of Experimental & Clinical Cancer Research 40, 1-17, 2021 | 50 | 2021 |
| Molecular subtype identification and prognosis stratification by a metabolism-related gene expression signature in colorectal cancer D Lin, W Fan, R Zhang, E Zhao, P Li, W Zhou, J Peng, L Li Journal of translational medicine 19, 1-15, 2021 | 37 | 2021 |
| Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma Q Ou, Y Yu, A Li, J Chen, T Yu, X Xu, X Xie, Y Chen, D Lin, Q Zeng, ... Annals of Translational Medicine 8 (5), 2020 | 20 | 2020 |
| Association of immune checkpoint inhibitor therapy with survival in patients with cancers with MUC16 variants Y Yu, D Lin, A Li, Y Chen, Q Ou, H Hu, H Yao JAMA Network Open 3 (6), e205837-e205837, 2020 | 16 | 2020 |
| Association of immune checkpoint inhibitor with survival in patients with cancers with protein tyrosine phosphatase receptor T mutation Z He, A Li, D Lin, Y Gu, Y Chen, Q Ou, L Li, H Yao, Y Yu Clinical and Translational Medicine 10 (6), 2020 | 7 | 2020 |
| Joint association of patients’ sex and PD‐L1 expression with overall survival benefits and tumor‐immune microenvironment in immune checkpoint inhibitors for cancers A Li, Y Chen, W Zhang, H Zhong, Q Ou, Y Gu, J Xia, D Lin, T Fu, R Liu, ... Clinical and Translational Medicine 10 (2), 2020 | 7 | 2020 |
| Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized … Y Yu, Y Chen, A Li, Q Ou, Q Li, Y Gu, D Lin, W Zhang, J Wang, X Tang, ... Clinical and Translational Medicine 10 (2), 2020 | 3 | 2020 |
| Benefits and risks from maintenance therapy after first-line chemotherapy in patients with metastatic breast cancer. Y Yu, Y Wang, Q Gao, Q Ou, D Lin, T Fu, H Yao Journal of Clinical Oncology 36 (15_suppl), 1088-1088, 2018 | 2 | 2018 |
| Role of neoadjuvant chemotherapy or chemoradiotherapy in oesophageal carcinoma. H Yao, Y Yu, Q Ou, Y Wang, Q Gao, T Fu, D Lin, S Wu Journal of Clinical Oncology 36 (15_suppl), 4040-4040, 2018 | 1 | 2018 |
| Comprehensive analyses of the clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer. Q Ou, T Fu, Y Yu, D Lin, Q Gao, Y Zhang, B Luo Journal of Clinical Oncology 36 (5_suppl), 168-168, 2018 | 1 | 2018 |
| Role of immune checkpoint inhibitor, tumor vaccine and cellular immunotherapy in advanced non-small-cell lung cancer. Y Yu, Y Wang, S Liu, Q Ou, T Fu, D Lin, Q Gao, Z Zhan, H Yao Journal of Clinical Oncology 36 (15_suppl), e21056-e21056, 2018 | | 2018 |
| Comparative efficacy and acceptability of first-line single-agent chemotherapy in metastatic breast cancer. Y Wang, Y Yu, Q Ou, Q Gao, T Fu, D Lin, H Yao Journal of Clinical Oncology 36 (15_suppl), e13082-e13082, 2018 | | 2018 |
| Efficacy of checkpoint inhibitors, tumor vaccines, and cellular immunotherapies in patients with advanced non-small cell lung cancer. Y Yu, Q Ou, Y Wang, Z Liu, T Fu, Q Gao, D Lin, H Yao Journal of Clinical Oncology 36 (5_suppl), 165-165, 2018 | | 2018 |
| Evaluation of the clinical benefits of immune checkpoint inhibitors in patients with advanced melanoma. Q Ou, Y Yu, D Lin, T Fu, Q Gao, B Luo Journal of Clinical Oncology 36 (5_suppl), 194-194, 2018 | | 2018 |
| Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients With Metastatic Breast Cancer After First-Line Chemotherapy Y Yu, H Hong, Y Wang, W Ren, Q Gao, YJ Chen, P Chen, J Zhao, Q Ou, ... | | |
